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Available online 5 November 2015AbstractIn the last two decades, numerous researchers have focused on elucidating the relationship between the skeletal and immune systems with respect
to their regulatory mechanisms. It has now become clear that osteoclasts are derived from the same myeloid precursor cells that can differentiate into
macrophages and myeloid dendritic cells. In addition, bone and immune cells coexist in the common microenvironment of the bone marrow and are
thus influenced by similar mediators. Discovery of a common regulatory mechanism via the receptor activator of nuclear factor kappa-B ligand
(RANKL)ereceptor activator of NF-kB (RANK)eosteoprotegerin (OPG) axis in both the bone and immune system has not only increased
understanding of the fundamental processes of bone homeostasis but has further crystalized understanding of the definitive regulatory correlation
between bone and immunity. Moreover, many of the soluble mediators produced by immune cells, including cytokines, chemokines, and growth
factors, regulate the activities of osteoclasts and osteoblasts. This increased recognition of the complex interactions between the immune system
and bone has led to the development of the interdisciplinary field of osteoimmunology. In this review, we summarize the characteristics of bone cells
and the soluble mediators responsible for crosstalk between the skeletal and immune systems. A more complete appreciation of the interactions
between immune and bone cells should lead to better therapeutic strategies for diseases that affect either or both systems.
© 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The skeletal system has long been regarded as a metabol-
ically inert organ; however, it is now well known that bone
remodeling is continuously and dynamically carried out in
order to maintain bone function and homeostasis. Recent re-
views have described findings in the new field of osteoim-
munology regarding the relationship between the skeletal and
immune systems and their overlapping regulatory mechanisms
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).development of immune cells that are derived from hemato-
poietic stem cells (HSCs) and influence the various cytokines
produced by immune cells to determine the fate of bone cells.
Indeed, bone is an ideal anatomic microenvironment for HSC
maintenance and differentiation, and recent data show that
osteoblasts, which are bone matrix-producing cells, regulate
the development of the HSC niche, from which all blood and
immune cells are derived. The regulation of bone by he-
matopoietic and immune cells produces a variety of physio-
logical and pathological effects. In pathological conditions
such as rheumatoid arthritis (RA) and inflammatory bowel
disease, infiltrating lymphocytes and other mononuclear cells
provide several key factors that influence bone metabolism by
altering the balance between bone-forming osteoblasts and
bone-resorbing osteoclasts. Whether or not these interactions
also influence normal bone homeostasis had been unclear until
the discovery of RANKL (also known as TNF-relatedElsevier B.V. This is an open access article under the CC BY-NC-ND license
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T cells and subsequent elucidation of its role as a pivotal factor
for osteoclastogenesis, which has provided critical evidence
that a physiological relationship exists between the normal
immune system and bone metabolism [3e5]. Here, we provide
a brief description of the current understanding of bone cells
(osteoclasts and osteoblasts) and the immune cell-derived
factors that regulate these cells and affect bone metabolism.
2. Characterizations of bone cells2.1. OsteoclastsOsteoclasts originate from HSCs that can differentiate into
macrophages and dendritic cells, and multinucleated giant
cells that form via the fusion of mononuclear precursor cells
[1,2], and have a unique capacity to efficiently resorb the bone
matrix. It has been conclusively demonstrated that RANKL
(also designated as TNFSF11) is an essential factor that con-
trols osteoclastogenesis and bone resorption both in vitro and
in vivo. Almost 20 years ago, four research groups indepen-
dently discovered and alternatively named this factor as
TRANCE, RANKL, osteoclast differentiation factor (ODF),
and osteoprotegerin ligand (OPGL). The first two groups [3,6]
demonstrated that TRANCE/RANKL and its receptor
(TRANCE-R/receptor activator of NF-kB [RANK]) are
expressed in activated T cells and dendritic cells, respectively,
and that these receptoreligand interactions promote dendritic
cell function and survival. The second two groups [4,5] found
that this cytokine is derived from bone marrow stromal cells
(BMSCs) and is an essential factor for in vitro osteoclasto-
genesis. These findings demonstrated that both the immune
and skeletal systems share the common RANKL/RANK/
osteoprotegerin (OPG) signal axis, leading to the first concept
establishing a functional connection between these systems.
Since the discovery of RANKL, a number of reviews have
been written that explain the molecular pathways regarding
the maturation of osteoclasts from bone marrow precursors
[1,5]. Therefore, we will here briefly describe recent progress
on the identification of the bone marrow cell population as
osteoclast precursors.
Mononuclear cells from the bone marrow, peripheral blood,
and spleen can differentiate into osteoclast-like cells (OCLs)
in various in vitro culture systems [1,3,4]. A portion of the cell
population from the murine bone marrow that did not express
Sca-1, but was positive for CD117/c-kit was identified as
osteoclast progenitors [2]. These cells produced tartrate-
resistant acid phosphatase (TRAP)-positive OCLs via culture
in semi-solid media or in co-culture with ST2 stromal cells
after treatment with 1a,25-(OH)2 vitamin D3. Arai et al. [7]
found that when c-kit-positive murine bone marrow cells
were cultured with ST2 stromal cells, RANKL, and macro-
phage colony-stimulating factor (M-CSF), this cell population
could differentiate into OCLs. These authors concluded that
bone marrow cells expressing c-kit, c-fms, and CD11blow
contained multipotent progenitor cells that frequently produce
osteoclasts. This cell population did not initially expressRANK (the receptor for RANKL), but its expression was
induced following M-CSF treatment. Interestingly, in methy-
cellulose culture, these progenitor cells differentiated into
macrophages and mononuclear TRAPþ cells, indicating their
multipotent ability. Subsequently, osteoclast precursor cells
were identified to be CD3, CD45R, and negative or low for
CD11b expression, but positive for c-fms expression [2,8].
According to the expression of c-kit, this population of bone
marrow cells was further separated into two categories. The
first, c-kithigh cells rapidly formed OCLs in vitro when cultured
with M-CSF and RANKL, and the second, c-kit low or c-kit-
cells slowly formed OCLs in vitro. This population of osteo-
clast precursors transiently expressed CD11b in vitro. Initially,
the population of c-kit low or c-kit- cells efficiently produced
OCLs; however, this cell population transiently formed
CD11bhigh mononuclear osteoclast precursors following M-
CSF and RANKL induction, and the expression of this antigen
disappeared in multinucleated cells [2].
Human and murine cells that express an early marker of the
myeloid dendritic cell lineage were found to differentiate into
osteoclasts in vitro, indicating that there is some connection
between osteoclasts and professional antigen-presenting den-
dritic cells [9]. In addition, it was shown that murine bone
marrow-derived and splenic CD11cþ dendritic cells, which are
activated by cytokines and can present antigens to T lym-
phocytes, developed into osteoclasts under M-CSF and
RANKL treatment [10]. Moreover, immature dendritic cells
were found to be able to differentiate into OCLs in response to
M-CSF and RANKL in vitro; however, neither mature myeloid
dendritic cells nor plasmacytoid dendritic cells formed OCLs
in culture [11]. This transdifferentiation was stimulated by
pro-inflammatory cytokines such as interleukin (IL)-1b and
tumor necrosis factor-alpha (TNF-a), and was inhibited by the
addition of interferon (IFN)-a as well as IL-2, IFN-g, and IL-
4. It was previously suggested that macrophages, osteoclasts,
and myeloid dendritic cells can differentiate from common
progenitor cells [9], and single-cell clones from mouse bone
marrow progenitor cells that are specific for macrophages and
resident spleen dendritic cells in vivo also differentiated into
these cells following treatment with the cytokines M-CSF and
granulocyte-macrophage colony-stimulating factor (GM-CSF)
in vitro [12]. Recently, more conclusive results were reported
with regards to the common progenitor cells for osteoclasts,
macrophages, and antigen-presenting dendritic cells at the
single-cell level [13]. Among the murine bone marrow cells
expressing B220CD3CD11b/low CD115þ and either
CD117high, CD117intermediate, or CD117low, which have high
osteoclastogenic potential, the population with a higher
CD117 expression level was able to generate osteoclasts,
macrophages, and dendritic cells in vitro with efficiencies of
over 90%. In addition, cells with osteoclastogenic potential
were also found in the blood and peripheral hematopoietic
organs. However, the relationship between the bone marrow
and peripheral monocyte progenitors remains unclear. In
addition to the bone marrow, circulating osteoclast precursor
cells expressing CD11b in the blood were identified, and
proliferation of these precursors was stimulated by inducing an
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[14]. Monocytes isolated from human peripheral blood
expressing CD14 were also identified as osteoclast precursors
[15]. Furthermore, several investigators have established the
osteoclastogenic potential of splenocytes in vitro, although the
specific condition for splenic osteoclastogenesis remains un-
known [16]. However, recent findings showing that osteoclast
differentiation and activation require various co-stimulatory
molecules, which act in concert with M-CSF and RANKL,
support the possibility of the important role of the splenic
microenvironment for osteoclastogenesis [1,13]. Adaptor
proteins function as co-stimulatory molecules for osteoclas-
togenesis, such as DNAX adaptor protein 12 (DAP12) and Fc
receptor g (FcRg) containing an immunoreceptor tyrosine-
based activation motif. These molecules have been found to
be associated with triggering receptor expressed by myeloid
cells-2 (TREM-2) and signal regulatory protein b1 (SIRPb1),
and with osteoclast-associated receptor (OSCAR) and paired
Ig-like receptor A (PIR-A), respectively [17,18]. Recently, it
was reported that OSCAR binds to specific motifs within
fibrillar collagens in the extracellular matrix and promotes
osteoclastogenesis in vivo [19]; however, the ligands for the
other factors are still unclear.2.2. OsteoblastsOsteoblasts are differentiated from multipotent mesen-
chymal stem cells (MSCs) and can also differentiate into
BMSCs, chondrocytes, and adipocytes [1,8]. In response to
stimuli, these progenitor cells commit to the osteogenic line-
age and differentiate into preosteoblasts, followed by differ-
entiation into lining cells and mature osteoblasts, although the
regulatory signals that drive the progenitor cells to an osteo-
blast fate have not been fully elucidated. However, a number
of critical paracrine signals and cell-autonomous transcription
factors, which are expressed at distinct time points during the
differentiation processes, have been identified.
Runt domain-containing transcription factor (Runx2) is an
essential transcription factor for osteoblast differentiation.
Runx2/ mice showed a complete lack of both intra-
membranous and endochondral ossification due to the absence
of osteoblast differentiation [20]. In addition, Runx2/ cal-
varial cells spontaneously differentiated into adipocytes and
differentiated into chondrocytes in culture with bone
morphogenetic protein 2 (BMP-2) in vitro, but they did not
differentiate into osteoblasts in vitro or in vivo, even in the
presence of BMP-2 [21]. Therefore, Runx2 plays a critical
role in the differentiation of multipotent MSCs into osteo-
blasts and inhibits their differentiation into adipocytes and
chondrocytes.
Osterix (Osx) is an essential factor for the commitment of
preosteoblasts differentiation into mature osteoblasts. Osx/
mice showed a completely lack of mineralized bone, whereas
the cartilaginous tissue was essentially normal [22]. In addi-
tion, mesenchymal cells from Osx/ mice expressed Runx2;
however, Osx was not expressed in Runx2/ mice. These
results demonstrate that Osx is a downstream gene of Runx2.Consistently, Osx expression has been found to be positively
regulated by direct binding of Runx2 to a responsive element
in the promoter of the Osx gene. Moreover, Osx/ mouse
embryos did not express osteoblast differentiation markers
such as osteocalcin, alkaline phosphatase (ALP), and others
[22]. Therefore, Osx is an osteoblast-specific transcription
factor that is required for bone formation and osteoblast
differentiation.
BMPs were identified as members of the transforming
growth factor-b (TGF-b) superfamily and have been shown to
induce ectopic bone formation in mice. Upon BMP binding to
BMPR-II (a subtype of BMP receptors), another receptor,
BMPR-I, is recruited to form an activated quaternary com-
plex, and then phosphorylates and activates intracellular
Smad protein. The Smad receptor binds to co-Smad and
translocates to the nucleus to serve as a transcription factor
[23]. One of the main target genes of the BMP-Smad com-
plex is Runx2. In a human BMSC line, BMP-2 treatment
enhanced osteoblast commitment via increasing the RUNX2
gene expression and ALP protein levels [8]. Recent studies
have shown that deletion of the genes encoding BMP ligands
or BMP receptors from the limb bud mesenchyme resulted in
severe impairment of osteogenesis or chondrogenesis,
respectively [24].
Wnt signaling is also a major molecular pathway involved
in osteoblastogenesis. Wnt signaling is categorized in two
pathways: the canonical pathway (through b-catenin) and the
non-canonical pathway (not requiring b-catenin). In the ca-
nonical pathway, Wnt binds to the transmembrane receptor
Frizzed and its co-receptor low-density lipoprotein receptor-
related protein 5 and 6 (LRP5/6). This process induces the
accumulation and stabilization of cytosolic b-catenin, which
enters the nucleus and stimulates the transcription of Wnt
target genes such as Runx2, Osx, and Fra-1/2 [2]. Promotion
of osteoblastogenesis via the non-canonical Wnt signaling
pathway was also identified in bone marrow mesenchymal
progenitors [25]. Wnt5A repressed PPAR-gamma trans-
activation and induced Runx2 expression through chromatin
inactivation, leading to the formation of osteoblasts from
MSCs. Therefore, both the canonical and non-canonical Wnt
signaling pathways are involved in regulation of the differ-
entiation of osteoblast progenitor cells into mature
osteoblasts.
3. Cytokines and immune cell-derived factors that
regulate bone cells and bone metabolism
Many cytokines, including pro-inflammatory cytokine
produced by immune cells such as macrophage and lympho-
cytes, regulate bone cell and bone metabolism as well as im-
mune response. In this section, we first describe the current
understanding of the roles of RANKL/RANK/OPG and M-
CSF, key regulators of bone metabolism, and next summarize
pro-inflammatory cytokines, which were categorized into three
groups (osteoclastogenic, anti-osteoclastogenic, and both)
depending upon their influence on osteoclast differentiation,
activation, and survival.
84 S.H. Lee, Y. Choi / Osteoporosis and Sarcopenia 1 (2015) 81e913.1. RANKL/RANL/OPG, and M-CSFIdentification of the functions of the interaction of
RANKL and its receptors (RANK and OPG) has led to the
emergence of the field of osteoimmunology, which is con-
cerned with the relationship between the immune and bone
systems. RANKL (TNFSF11), a member of the TNF super-
family (TNFSF), is a type II membrane protein showing close
homology to other TNFSF members such as TRAIL, FasL,
and TNF-a. Both murine and human RANKL consists of a C-
terminal extracellular receptor-interacting domain and a
transmembrane domain, but is found in both membrane-
bound and soluble forms [26]. It has been reported that
various cells and tissues, including T lymphocytes, osteo-
blasts, bone marrow stromal cells, and the lung, express
RANKL [4,12,26]. In addition, osteocytes were recently
identified as a major source of RANKL production via
observation of mice lacking RANKL specifically in osteo-
cytes [27]. Expression of RANKL is induced and regulated by
various cytokines and growth hormones, including gluco-
corticoid, 1a,25-(OH)2 vitamin D3, IL-1, TNF-a, parathyroid
hormone (PTH), prostaglandin E2 (PGE2), TGF-b, Wnt li-
gands, and lipopolysaccharide [28]. RANKL-deficient mice
showed severe osteopetrosis and defective tooth eruption
owing to the complete lack of osteoclasts. In addition, these
mice exhibited an inability of the early differentiation of T
and B lymphocytes, and showed deficiency of all lymph
nodes, even though the splenic structure and Peyer's patches
were normal [29].
RANK (TNFRSF11A) is the signaling receptor for
RANKL and is specifically expressed on osteoclast precursor
cells upon M-CSF induction. Upon the RANKL-RANK
interaction, tumor necrosis factor receptor-associated factors
(TRAFs) are recruited and bind to the cytoplasmic domain of
RANK. TRAF6, a major adaptor molecule in RANKL-RANK
signaling, mediates the activation of the mitogen-activated
protein kinases (MAPKs) p38 and JNK, as well as the ca-
nonical NF-kB pathway in response to RANK signaling [30].
Similar to RANKL knockout (KO) mice, RANK-deficient
mice exhibited severe osteopetrosis via impairment of osteo-
clastogenesis and the complete lack of all peripheral lymph
nodes, except for mucosal-associated lymphoid tissues [31].
Thus, RANKL and RANK are critical factors for osteoclas-
togenesis and are essential regulators of lymph-node organo-
genesis in vivo.
OPG, also designated as TNFRSF11B, is known primarily
as a soluble decoy receptor that modulates interactions be-
tween ligands and signaling receptors, especially RANKL and
RANK. BMSCs and osteoblasts are the main producers of
OPG, but it can also be induced in B lymphocytes, dendritic
cells, and follicular dendritic cells. In contrast to RANKL and
RANK KO mice, OPG-deficient mice exhibited severe oste-
oporosis accompanied with a high incidence of fractures, and
also showed calcification of the aorta and renal arteries [32]. A
number of recent reviews have been published that have
elucidated the diverse physiological functions of the
RANKLeRANKeOPG signaling axis in the skeletal andimmune systems [1,20,28]. A brief summary of the
RANKLeRANKeOPG axis is presented in Fig. 1.
M-CSF is expressed by osteoblasts and BMSCs and regu-
lates the development, maintenance, and function of numerous
myeloid cells, including osteoclasts. M-CSF binds to its re-
ceptor (c-Fms) expressed on monocyte/macrophage lineage
cells. The importance of this cytokine in osteoclast differen-
tiation was demonstrated from experiments in spontaneous op/
op mutant mice. This mouse model exhibited defective
macrophage/monocyte formation via deficiency in M-CSF
expression, and showed congenital osteopetrosis due to a se-
vere deficiency of osteoclasts, thereby underlying the impor-
tance of M-CSF for osteoclast development [1,2]. M-CSF
injections or osteoblast-specific expression of M-CSF in op/op
mice restored the defect in osteoclast formation and bone
resorption [8]. In addition, M-CSF induced the proliferation
and differentiation of osteoclast precursor cells, and also
regulated osteoclast apoptosis, resulting in prolonged mature
osteoclast survival [33]. In osteoclast precursors, M-CSF is
also a potent stimulator of RANK expression, and is essential
for expansion of the osteoclast precursor pool.3.2. Pro-inflammatory cytokines having osteoclastogenic
effectsTNF-a was reported to induce the formation of osteoclasts
from bone marrow macrophages in vitro, and to enhance
osteoclast formation and bone resorption in vivo [1]. In the
presence of TNF-a, low concentrations of RANKL showed a
synergistic effect to promote osteoclast formation in vitro and
in vivo; however, TNF-a alone did not induce osteoclast dif-
ferentiation [34]. The osteoclastogenic effect of TNF-a in a
co-culture of osteoclast precursors and stromal cells was found
to be mediated by IL-1 via enhancing RANKL expression on
stromal cells and through direct stimulation of osteoclast dif-
ferentiation precursors [35]. Thus, TNF-a is considered to
increase RANKL signaling. Although in vivo administration of
TNF-a to RANK-deficient mice produced only a few osteo-
clasts, TNF-a directly stimulated in vitro osteoclast formation
in a RANK-independent manner in cultures of cells from
RANK-deficient mice [36]. From the perspective of osteo-
blastogenesis, TNF-a is classically known to have an inhibi-
tory effect on osteoblast differentiation and collagen synthesis,
which is caused by the repression of insulin-like growth factor-
1 (IGF-1), Osx, and Runx2 [37]. In human MSCs, TNF-a also
inhibited Runx2 and collagen synthesis; however, ALP activ-
ity and matrix mineralization were increased [38]. In addition,
TNF-a induced apoptosis of osteoblasts, presumably through
FaseFas ligand signaling [28]. Interestingly, both TNF re-
ceptor 1 and TNF receptor 2-deficient mice show normal bone
phenotypes, suggesting that TNF-a affects the bone only in
inflammatory states, rather than during normal development.
Conversely, TNF-a has exhibited a dual effect on the osteo-
genic differentiation of MSCs from rodents and humans. At
low concentrations, TNF-a increased osteogenic differentia-
tion via promotion of Runx2, Osx, osteocalcin, ALP, and
BMP-2 levels, while higher concentrations of TNF-a down-
Fig. 1. A schematic diagram of the RANKLeRANKeOPG axis in osteoclastogenesis. Osteoblasts, which are responsible for bone matrix formation, produce
RANKL in response to many inflammatory cytokines and calcitropic factors such as 1a,25-(OH)2 vitamin D3, PGE2, TNF-a, IL-1, IL-6, and PTH. Induced
RANKL may bind to its receptor, RANK, which is expressed on osteoclast precursor cells. This binding evokes the differentiation of osteoclast precursor cells to
preosteoclasts expressing tartrate-resistant acid phosphatase (TRAP) and calcitonin receptor. Mononuclear preosteoclasts then fuse together to become
nonfunctional multinucleated osteoclasts that are polykaryons lacking ruffled borders, and thus cannot resorb bone. These cells are activated into functional mature
osteoclasts with the capacity to resorb bone. RANKL participates in all steps of osteoclastogenesis, differentiation, fusion, and activation in vitro and in vivo.
Osteoblasts as well as bone marrow stromal cells also produce M-CSF, which binds to its receptor c-Fms, expressed on monocyte/macrophage lineage cells
(osteoclast precursor cells). M-CSF has important roles in the proliferation and survival of osteoclasts as well as their differentiation. M-CSF is also a potent
stimulator of RANK expression. Bone marrow stromal cells and osteoblasts produce OPG, a decoy receptor for RANKL, to modulate osteoclastogenesis. OPG can
bind to RANKL and inhibits the interaction between RANKL and RANK. Initially, the RANKLeRANKeOPG signaling axis was identified from the immune
system. A delicate balance of the RANKLeRANKeOPG signaling axis is necessary for regulation of both bone metabolism and the immune system.
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osteoblastogenesis is directly dependent on the TNF-a con-
centration, cell type, and exposure time. The paradoxical ef-
fects of TNF-a occur depending on the differentiation stage of
the responding cells [37].
IL-1a and IL-1b, two distinct IL-1 gene products, show
identical activity and are members of the IL-1 family, which
consists of 11 members and plays a central role in the regu-
lation of immunity and inflammation. IL-1 is a potent stimu-
lator of in vitro and in vivo bone resorption. IL-1, produced in
the bone, affects osteoclasts both directly and indirectly via
enhancing RANKL production and its activity, resulting in
stimulation of osteoclastogenesis [1,2,8]. In addition, IL-1
partially mediates osteoclast formation by RANKL and
1a,25-(OH)2 vitamin D3 stimulation from in vitro co-culture
[1,8,28]. IL-1 also enhances the production of OPG, a decoy
receptor of RANKL, and prostaglandin synthesis in the bone,
which may explain some of its resorptive activity [40]. In fact,
PGE2 enhances the production of RANKL by inflammatory
stimuli, and thus regulates osteoclastogenesis and resorptive
activity [8]. Furthermore, IL-1 also stimulates osteoblastic
cells to produce M-CSF in a dose-dependent manner and in-
hibits osteoclast apoptosis [40]. IL-1-induced osteoclasto-
genesis in co-culture of murine stromal cells and
hematopoietic cells was found to be dependent on RANKL but
not TNF-a [41]. The effects of IL-1 on stimulation of RANKL
production and prolongation of osteoclast survival were found
to be dependent on the expression of myeloid differentiationfactor 88 (MyD88), PI3K/AKT, and ERK, but not Toll/
interleukin-1 receptor domain-containing adaptor inducing
interferon-b (TRIF) [8,28]. Furthermore, IL-1 also inhibits
osteoblastogenesis via modulation of MAPK, causing down-
regulation of new bone formation. IL-1 also stimulates
Dickkopf-related protein 1 (DKK1) and sclerostin (SOST),
which may suppress osteoblast differentiation via inhibition of
Wnt signaling [42].
IL-6 family cytokines, including IL-6, IL-11, leukemia
inhibitory factor (LIF), and oncostatin M (OSM), which share
the same receptor subunit and often have similar functions, are
known to regulate both osteoclast and osteoblast differentia-
tion, although IL-6-mediated bone resorption varies depending
on the in vitro assay system employed [2]. IL-6 is a multi-
functional cytokine with a wide variety of activities and is
produced by osteoblastic cells and BMSCs. The receptor for
IL-6 (IL-6R) has two subunits, a ligand-binding and a com-
mon signal-transducing subunit, glycoprotein 130 (gp130),
which are required for the tyrosine phosphorylation of STAT3
[8]. An in vitro study with dominant-negative STAT3 and
gp130, the activation of the signaling pathway through IL-6/
soluble IL-6R/STAT3 induced the expression of RANKL on
osteoblasts, indicating stimulation of osteoclastogenesis [43].
However, in an in vivo experiment with IL-6 transgenic mice,
osteoclast number and bone resorption decreased due to the
absence of soluble IL-6 receptor under physiological condi-
tions [44]. In addition, IL-6 with soluble IL-6R significantly
stimulated bone resorption via enhancement of RANKL and
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RANK expression on osteoclast progenitors [45]. These results
demonstrate the complexity of the function of IL-6 for bone
metabolism. Furthermore, the expression of IL-6 decreased
following estrogen treatment in osteoblasts, and ovariectomy
(OVX)-induced bone loss was protected by treatment of a
neutralizing antibody against IL-6 or by delection of the IL-6
gene [46]. These results strongly suggested that IL-6 is an
essential factor for the bone loss caused by estrogen deficiency
leading to postmenopausal osteoporosis. In addition, IL-6
appears to mediate pathological conditions characterized by
excessive bone loss, including Paget's disease, hypercalcemia
associated with malignancy, fibrous dysplasia, multiple
myeloma, and GorhameStout disease [8]. IL-11, which is
produced by bone cells in response to resorption stimuli,
stimulates osteoclast formation and bone resorption in vitro,
but has no effect on isolated mature osteoclasts. IL-11 re-
ceptor-deficient mice exhibited increased trabecular bone mass
associated with down-regulated osteoclast numbers and bone
resorption. This result was reproduced in ex vivo cultures,
which showed decreased bone turnover, osteoclast formation,
and resorption activity [47]. Like IL-6, LIF is produced by
osteoblasts in response to resorption stimuli such as PTH,
resulting in a variable effect on bone resorption. LIF was
found to stimulate osteoclastogenesis and bone resorption via
a prostaglandin-independent or dependent manner in vivo and
in vitro [48], whereas it has also been shown to have a potent
inhibitory effect on bone resorption [49]. LIF also enhanced
both RANKL and OPG expression in murine calvaria cultures
[45]. However, mice with targeted deletion of the LIF receptor
gene exhibited a reduced bone volume and increased osteo-
clast numbers, resulting in severe osteopenia [50]. OSM is
produced within the bone microenvironment by osteocytes,
osteoblasts, macrophages, and T lymphocytes. In co-culture of
bone marrow cells with osteoblasts, OSM stimulates osteoclast
formation via enhancement of RANKL expression by osteo-
blasts. In addition, OSM can inhibit the production of scle-
rostin, a bone formation inhibitor [51]. In contrast, OSM
inhibited 1,25-(OH)2 vitamin D3-stimulated OCL formation in
human bone marrow cultures, and decreased bone resorption
rates in fetal mouse long bone cultures. Moreover, over-
expression of OSM in transgenic mice induced an osteope-
trotic phenotype [52]. Hence, the effect of OSM in bone
metabolism remains controversial.
Chemokines are a family of small cytokines, i.e., signaling
proteins that direct the recruitment and homing of myeloid
cells expressing their receptors. Chemokines can be classified
into four main subfamilies, CXC, CC, CX3C, and XC,
depending on the sequence motif containing the first cysteine
(C) residue. Chemokines exert their biological effects by
interacting with G protein-coupled transmembrane receptors
to initiate cytoskeletal rearrangement, adhesion, and direc-
tional migration [53]. IL-8 is a CXC chemokine produced by
macrophages and other cell types, including osteoclasts. IL-8
directly stimulates the differentiation of human peripheral
blood mononuclear cells (PBMCs) into osteoclasts and bone
resorption through the RANKL-RANK-independent pathway[54]. In addition, IL-8 has been implicated in the lytic bone
lesions associated with metastatic cancers, and also found to
be partially involved in modulation of bone resorption by
enhanced expression of inducible nitric oxide synthase (iNOS)
in osteoclasts [55]. CXCL12 (also termed stromal-derived
factor-1 or B cell-stimulating factor) produced by BMSCs
and osteoblasts, and its receptor CXCR4 play crucial roles in
the regulation of hematopoietic cell homeostasis and the im-
mune response [56]. CXCR4 is markedly expressed in osteo-
clast precursor cells and its expression is downregulated
during differentiation to the osteoclast linage. CXCL12, as a
regulator of bone resorption, has also been shown to be
involved in the migration of osteoclast precursors to resorption
sites, their maintenance within the bone microenvironment,
and enhanced RANKL-induced osteoclastogenesis [56]. In
addition, the expression of CXCL12 was significantly
increased in osteoclasts differentiating on calcium phosphate-
coated slides [57]. Recent studies have also implicated
CXCL12 in the pathogenesis of several diseases, including RA
and multiple myeloma [58]. CCL2 (also termed monocyte
chemoattractant protein-1), the ligand for CCR2, is a chemo-
kine known to recruit monocytes and macrophages to sites of
inflammation, and is highly expressed in osteoblasts associated
with inflammatory lesions induced by proinflammatory cyto-
kines [59]. In the presence of RANKL, CCL2 significantly
enhanced OCL formation, and PTH-treated osteoblasts
induced CCL2 expression and enhanced the recruitment and
fusion of preosteoclasts [60]. In addition, CCL2 was found to
be specifically expressed in osteoclasts, and CCL2-deficient
mice exhibited down-regulated osteoclast differentiation and
NFATc1 expression, in which treatment of CCR2 in the
presence of RANKL restored osteoclastogenesis [61].
Recently, CCL2 has been implicated in tumor progression and
bone metastasis through recruitment of macrophages and os-
teoclasts to the tumor site [62]. CCL3 (also known as
macrophage inflammatory protein-1a) is expressed in the bone
and bone marrow cells, and directly stimulates osteoclast
formation through its receptors CCR1 and CCR5 [8]. It was
also shown to mediate the osteolytic lesions in multiple
myeloma through induction of RANKL expression by stromal
cells [63]. Recently, in an experiment with CCL3-deficient
mice, CCL3 was found to partially participate in decreased
bone remodeling induced by mechanical loading during or-
thodontic tooth movement [64]. RANKL dramatically induced
the expression of CCL9 (also termed macrophage inflamma-
tory peptide-1g) and its receptor CCR1 on osteoclasts. In
addition, CCL9 stimulated osteoclast differentiation, survival,
and activation for bone resorption [65]. Treatment of M-CSF
to Csf1-null toothless (tl/tl ) rats was found to enhance
osteoclastogenesis and bone resorption, and strongly induced
the expression of CCL9 and its receptor CCR1 in the bone.
Moreover, anti-CCL9 antibody inhibited osteoclast differen-
tiation in cultures and suppressed the osteoclast response in M-
CSF-treated tl/tl rats [66]. A more recent study showed that
locally inhibiting CCL9 expression by small hairpin RNA
treatment ameliorated osteoarthritis progression in mice;
treated mice showed less severe osteoarthritis through
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metalloproteinase-13 expression than control mice [67].
CCL20 (also known as macrophage inflammatory protein-3a)
was significantly increased in RA synovial fluid, and proin-
flammatory cytokines induced the expression of CCL20 in
isolated synovial fibroblasts. In addition, CCL20 directly
induced both osteoblast proliferation and osteoclast differen-
tiation [68].
IL-15 is a member of the IL-2 superfamily and shows
similar activity to IL-2 with respect to the stimulation of many
cell types, including lymphocytes and hematopoietic progen-
itor cells. IL-15 increased the formation of OCLs through
enhancing the number of osteoclast progenitor cells, but IL-2
could not replace the effect of IL-15 on osteoclastogenesis [2].
In addition, IL-15 was produced on T cells and monocytes
from the peripheral blood and synovial fluid of RA patients,
and was associated with enhanced osteoclast differentiation
and bone destruction of RA patients. A recent study suggested
that IL-15 promotes osteoclast formation, and significantly
upregulates the expression of RANKL and phospholipase D-1
(PLD1) via activation of the MAPKs and NF-kB pathways in
rheumatoid synovial fibroblasts. Interestingly, the treatment of
short interfering RNA against PLD1 markedly repressed IL-
15-stimulated RANKL and PLD1 expression [69].
IL-17 consists of at least six members, IL-7AeF, that play
central roles in adaptive immune responses and in the products
of the TH17 population, a subset of CD4 T lymphocytes with a
unique cytokine expression pattern [2]. IL-17A was initially
known to stimulate osteoclast differentiation in a co-culture of
bone marrow cells and osteoblasts via stimulation of PGE2
and RANKL expression in osteoblasts [70]. In addition, IL-17
levels were significantly increased in the synovial fluids,
indicating that it might be involved in the activation of oste-
oclasts and joint destruction of RA patients. Blocking IL-17A
with its specific antibody inhibited bone erosion by sup-
pressing inflammation in an arthritis model, and decreased the
synovial expression of both IL-1b and TNF-a [71]. IL-17 also
directly induced osteoclastogenesis from human monocytes
alone without osteoblasts, and this effect was potently
repressed by treatment with an anti-TNFa antibody [72]. On
the other hand, the functions of IL-17 were also demonstrated
in human mesenchymal stem cells (hMSCs). IL-17 stimulated
the proliferation of hMSCs and their differentiation into os-
teoblasts in a manner dependent on the generation of reactive
oxygen species, as well as osteoclastogenesis by induction of
M-CSF and RANKL expression [73].3.3. Pro-inflammatory cytokines having anti-
osteoclastogenic effectsIL-10, which is produced by activated T and B lympho-
cytes, inhibited bone resorption in both bone marrow cultures
and in a co-culture of BMSCs with spleen cells via repression
of osteoclast differentiation resulting from down-regulation of
NFATc1 expression and nuclear translocation, as well as
suppression of c-Fos and c-Jun expression [8]. In addition, IL-
10 also suppressed osteoblastogenesis via down-regulation ofbone proteins, including ALP and collagen type 1, and via
inhibition of the formation of mineralized bone matrix [74].
Like IL-8, IL-10 also upregulated the production of iNOS and
nitric oxide (NO) in osteoclasts, causing modulation of bone
resorption [55]. After dental pulps were infected with end-
odontic pathogens, IL-10-deficient mice showed significantly
increased infection-induced bone resorption through regula-
tion of IL-1a production by macrophages [75]. A recent study
demonstrated that IL-10 also suppressed the induction of co-
stimulatory signals by ITAM-coupled receptor, especially in-
hibition of TREM-2 expression, during RANKL-mediated
human osteoclastogenesis [76].
IL-18, also known as IFN-g-inducing factor and a member
of the IL-1 superfamily, is produced by osteoblasts and in-
hibits osteoclast formation due to its action upon T cells to
stimulate the expression of GM-CSF, but in a manner inde-
pendent of IFN-g production [8]. However, a recent study
showed that IL-18 inhibited TNF-a-mediated osteoclasto-
genesis in vivo in a T cell-independent manner [77]. IL-18 has
been shown to upregulate the expression of OPG, but not
RANKL, in stromal/osteoblastic cells. In addition, IL-18 was
identified as a mitogen for osteogenic cells in vitro and stim-
ulated INF-g production in the bone. In IL-18-overexpressing
transgenic mice, the number of osteoclasts decreased, although
so did bone mass, suggesting that IL-18 may also affect bone
growth [2]. Surprisingly, IL-18 has also been shown to indi-
rectly stimulate osteoclastogenesis through its effects on T
lymphocytes [78]. The expression level of IL-18 increased at
inflammation sites, including in RA and periodontitis.
Recently, IL-18 was found to enhance RANKL expression and
also increased the RANKL/OPG ratio in human fibroblast-like
synoviocytes in RA. Therefore, the net effect of IL-18 may
promote osteoclast formation and bone resorption [79].
IFNs were originally recognized for their potent antiviral
activity; however, they are now known to also profoundly
affect many other cellular and body functions, including dif-
ferentiation of bone cells and bone metabolism. INFs have
been classified into three major types: type I (INF-a, b, ε, k,
and u), type II (INF-g), and type III. First, IFN-g inhibited IL-
1-stimulated bone resorption, and also partially suppressed
osteoclast formation induced by 1,25-(OH)2 vitamin D3, PTH,
and IL-1, resulting in inhibition of bone resorption [31]. In
addition, INF-g significantly inhibited osteoclastogenesis via
RANKL-RANK signaling by accelerating the degradation of
TRAF6 via activation of the ubiquitin-proteasome system
[80]. Conversely, INF-g was also reported to indirectly stim-
ulate osteoclast formation and promote bone resorption by
stimulating antigen-dependent T cell activation and secretion
of RANKL and TNF-a in T cells [81]. From the perspective of
osteogenics, IFN-g inhibited proliferation of osteoblasts and
1,25-(OH)2 vitamin D3-stimulated osteocalcin production, and
showed variable effects on osteoblast differentiation. Recently,
treatment of IFN-g in primary osteoblast cultures was shown
to increase NO and PGE2, and to decrease cell viability [82].
In addition, nodule formation was also found to be reduced by
IFN-g treatment. In vivo experiments involving intraperitoneal
INF-g injections induced osteopenia in rats, and long-term
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increased bone resorption, which may be due to its effect in
stimulating osteoclast formation [2,83]. With respect to type I
IFNs (especially IFN-a and IFN-b), RANKL was found to
induce INF-b expression in osteoclast precursor cells, and
IFN-b inhibited osteoclast differentiation via suppression of
RANKL-mediated c-Fos expression. These effects were
confirmed in mice deficient in IFNAR1, a receptor component
of IFN-a/b, which exhibited severe osteopenia and enhanced
osteoclastogenesis [84]. Interestingly, RANKL also induced
the expression of SOCS-1 and -3, suppressors of IFN signaling
[85]. Therefore, although IFN-b induced by RANKL inhibits
osteoclastogenesis properties, the induction of signaling sup-
pressors by RANKL may rescue the inhibitory effects of IFN-
b. In addition, IFN-a modulated the proliferation and differ-
entiation of human osteoprogenitor cells through upregulation
of BMP-2, estrogen receptor-a, and osteocalcin mRNA
expression in ascorbate/dexamethasone cultures [86]. The
treatment of IFN-a in RANKL-mediated osteoclastogenesis
with human PBMCs also resulted in reduced osteoclast dif-
ferentiation and bone resorption via downregulation of c-Fos
[87]. However, IFN-a did not have an effect on bone turnover
in vivo, in contrast to IFN-g [88].3.4. Pro-inflammatory cytokines having dual effects on
osteoclatogenesisIL-7 is a multifunctional cytokine involved in the regula-
tion of hematopoiesis, and plays non-redundant roles in
supporting B- and T-cell lymphopoiesis. Studies have
demonstrated that IL-7 also regulates bone homeostasis [89];
however, IL-7 shows controversial effects on osteoclasts and
osteoblasts because of its various target cell-dependent ac-
tions. In vivo and in vitro neutralization studies with anti-IL-7
showed that IL-7 may inhibit OVX-induced bone loss as well
as act as a critical factor in early B cell development [90]. In
addition, systemic administration of IL-7 induced inflamma-
tory bone loss and osteoclast formation via the production of
soluble osteoclastogenic cytokines by T cells [91]. Impor-
tantly, IL-7 did not induce secretion of RANKL and TNF-a
by splenic T cells or bone loss in T cell-deficient mice [92]. In
addition, the disruption of T cell development and bone ho-
meostasis by OVX was mediated by IL-7. Although the effect
of IL-7 on bone homeostasis was elucidated, the secondary
effects of IL-7 resulting from the production of bone-
resorbing cytokines by T cells complicate the interpretation
of results obtained from in vivo IL-7 treatment studies
[91,92]. Furthermore, the direct inhibitory effect of IL-7 on
RANKL-induced osteoclastogenesis in a culture of bone
marrow cells was reported [93]. IL-7-deficient mice also
exhibited significantly increased osteoclast numbers and
decreased trabecular bone mass [94]. In addition, the OVX-
induced trabecular bone loss of IL-7-deficient mice was
comparable to that of wild-type mice. Addition of IL-7 to
neonatal calvaria in vitro inhibited new bone formation, and
injection of IL-7 into mice in vivo blocked bone formation via
down-regulation of Cbfa1/Runx2 [89]. Recently, micespecifically overexpressing human IL-7 in osteoblasts
exhibited augmented trabecular bone mass in vivo and
reduced osteoclast formation in vitro [95]. Moreover, targeted
overexpression of IL-7 in osteoblasts rescued the osteoporotic
bone phenotype and B-cell development of IL-7 KO mice,
although these effects were observed only in females. These
results demonstrate that IL-17 shows both direct inhibitory
effects on osteoclastogenesis in vivo and a differential
response between the sexes.
In general, IL-12 is considered to inhibit osteoclasto-
genesis; however, the underlying mechanism of its effects is
under debate. Although IL-12 did not inhibit osteoclast for-
mation in RANKL-pretreated cells, a direct inhibitory effect of
IL-12 on RANKL-mediated osteoclastogenesis in osteoclast
precursors and RAW 264.7 cells via down-regulation of
NFATc1 was reported [96]. In contrast, previous studies
demonstrated an indirect inhibitory effect of IL-12 on osteo-
clastogenesis. The inhibitory effect of IL-12 on osteoclasto-
genesis in a co-culture of osteoblasts and spleen cells was
mediated by T cells, and this effect was not affected by INF-g
and GM-CSF stimulation [8]. Conversely, another group
demonstrated that inhibition of RANKL-mediated osteoclas-
togenesis by IL-12 was caused by INF-g, which was possibly
induced from a non-T cell population [8]. In addition, IL-12
inhibited TNF-a-stimulated osteoclast differentiation and
induced apoptotic changes by interaction of FaseFasL in a T
cell-independent manner [97].
IL-23, which is a critical factor for TH17 differentiation and
proliferation, stimulated osteoclast formation in cultures of
hPBMCs without osteoclasts or RANKL treatment. IL-7,
TNF-a, and RANKL are considered to be involved in IL-23-
induced osteoclastogenesis [98]. Moreover, blocking of IL-
23 by its specific antibody delayed bone destruction in rats
with collagen-induced arthritis. IL-23 indirectly stimulated
osteoclastogenesis by upregulation of IL-17 release and
RANKL expression from CD4 T lymphocytes. In addition,
recent data showed that systemic IL-23 exposure induced
chronic arthritis, osteoclast differentiation, and severe bone
loss via expansion and activation of myeloid cells [99].
Conversely, RANKL-induced osteoclastogenesis from bone
marrow cells was partially inhibited by IL-23 through acti-
vated T cells [100].
4. Conclusions
To date, several studies conducted under physiological and
pathological conditions have contributed to remarkable ad-
vancements in understanding the relationship between the
immune system and bone metabolism. However, despite the
extensive crosstalk between these systems, the detailed
mechanisms underlying their cross-regulation remain poorly
understood. Recently, interesting data emerging from human
studies as well as animal models have illustrated the specific
interplay between the skeletal and immune systems. Further
investigations of intersystem crosstalk will provide valuable
knowledge as to how bone and the immune system are
physiologically regulated. Moreover, this effort may lead to
89S.H. Lee, Y. Choi / Osteoporosis and Sarcopenia 1 (2015) 81e91better therapeutic treatments for pathological conditions,
including inflammatory and metabolic bone diseases as well as
tumor-induced bone lysis.
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